DMD and muscular dystrophy: Since BGP-15 adjuvant therapy preserved skeletal muscle contractile function, which has previously been shown in other myopathic models [27,31,32,67], the reduction in both dystrophin and β-dystroglycan expression appears not to have the same impact on muscle function as it does in muscular dystrophy models.